NCT05471037

Brief Summary

Investigation of underlying metabolic mechanisms and impact on the two surgical procedures on inflammatory factors.

Trial Health

75
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P50-P75 for not_applicable

Timeline
4mo left

Started Aug 2022

Longer than P75 for not_applicable

Geographic Reach
1 country

1 active site

Status
active not recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Aug 2022Oct 2026

First Submitted

Initial submission to the registry

March 21, 2022

Completed
4 months until next milestone

First Posted

Study publicly available on registry

July 22, 2022

Completed
10 days until next milestone

Study Start

First participant enrolled

August 1, 2022

Completed
4.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2026

Last Updated

April 29, 2026

Status Verified

April 1, 2026

Enrollment Period

4.2 years

First QC Date

March 21, 2022

Last Update Submit

April 28, 2026

Conditions

Outcome Measures

Primary Outcomes (1)

  • Change in glucose tolerance

    Change in glucose tolerance as measured by plasma glucose concentrations at 120 minutes after ingestion of a standardized liquid test meal, pre-OP and 6-8 months post-OP.

    pre-OP and 6-8 months post-OP

Secondary Outcomes (35)

  • glycemic control

    pre-OP and 6-8 months post-OP

  • intestinal glucose absorption rate

    pre-OP and 6-8 months post-OP

  • gastrointestinal peptides

    pre-OP and 6-8 months post-OP

  • intestinal enteroendocrine cells

    pre-OP and 6-8 months post-OP

  • intestinal macrophages

    pre-OP and 6-8 months post-OP

  • +30 more secondary outcomes

Study Arms (3)

Long Biliopancreatic Limb LRYGB

ACTIVE COMPARATOR

25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.

Procedure: Long Biliopancreatic Limb LRYGB

Short Biliopancreatic Limb LRYGB

ACTIVE COMPARATOR

25 morbidly obese patients undergoing gastric bypass surgery, participating in SLIM Trial.

Procedure: Short Biliopancreatic Limb LRYGB

Control

NO INTERVENTION

15 normal weight control group without surgery.

Interventions

LRYGB with an 180 cm biliopancreatic limb (BPL) and an alimentary limb (AL) of 80 cm.

Long Biliopancreatic Limb LRYGB

Standard LRYGB with a 80 cm BPL and a 180 cm long AL.

Short Biliopancreatic Limb LRYGB

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • x 25 patients with morbid obestiy (BMI of 35 kg/m2 or higher) who comply with the regulatory rules for bariatric surgery in Switzerland (SMOB guidelines) and participate in the SLIM Trial
  • healthy lean controls

You may not qualify if:

  • general contraindications to kind of surgery
  • known or suspected non-compliance
  • inability to follow the procedures of the study, e.g. due to language problems, psychological disorders etc. of the participant
  • participation in another interventional study
  • BMI \> 60 kg/m2
  • height \< 145 cm
  • CL length of \< 180 cm as measured intraoperatively
  • ASA physical status classification \> III
  • inflammatory bowel disease
  • diabetes
  • intake of corticosteroids, anti-inflammatory/ immunosuppressive drugs potentially altering immune cells
  • clinical signs of current infection
  • known anemia (e.g. hemoglobin \< 110g/L for males, \< 100g/L for females)
  • known neutropenia (e.g. leucocyte count \< 1.5 x 10\^9/L or ANC \< 0.5 x 10\^9/L)
  • known immunodeficiency, e.g. HIV
  • +8 more criteria

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

St Clara Research Ltd, St Claraspital Basel

Basel, 4002, Switzerland

Location

MeSH Terms

Conditions

Obesity, Morbid

Condition Hierarchy (Ancestors)

ObesityOverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and Symptoms

Study Officials

  • Anne Christin Meyer-Gerspach, PD Dr. phil. II Dr. habil.

    St. Clara Forschung AG / St. Claraspital AG

    PRINCIPAL INVESTIGATOR
  • Bettina Wölnerhanssen, PD Dr. med.

    St. Clara Forschung AG / St. Claraspital AG

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
BASIC SCIENCE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 21, 2022

First Posted

July 22, 2022

Study Start

August 1, 2022

Primary Completion (Estimated)

October 1, 2026

Study Completion (Estimated)

October 1, 2026

Last Updated

April 29, 2026

Record last verified: 2026-04

Locations